Showing 11,681 - 11,700 results of 74,781 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 1.38s Refine Results
  1. 11681

    Effect of Molecular Structure on the B3LYP-Computed HOMO–LUMO Gap: A Structure −Property Relationship Using Atomic Signatures by Ahmed Mohamed (628889)

    Published 2025
    “…The atomic fragments containing π-bonds in various aromatic compounds were found to be the most significant atomic Signatures, explaining nearly 50% of the variance in the data, with regression coefficients that decreased <i>E</i><sub>gap</sub>. …”
  2. 11682

    The Strong <i>In Vivo</i> Anti-Tumor Effect of the UIC2 Monoclonal Antibody Is the Combined Result of Pgp Inhibition and Antibody Dependent Cell-Mediated Cytotoxicity by Gábor Szalóki (631712)

    Published 2014
    “…However, this inhibition is partial, since UIC2 binds only to 10–40% of cell surface Pgps, while the rest becomes accessible to this antibody only in the presence of certain substrates or modulators (e.g. cyclosporine A (CsA)). The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC<sub>50</sub> of doxorubicin (DOX) in KB-V1 (Pgp<sup>+</sup>) cells <i>in vitro</i> almost to the level of KB-3-1 (Pgp<sup>-</sup>) cells. …”
  3. 11683

    DataSheet1_Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.DOCX by Chuchu Zhang (2562154)

    Published 2021
    “…This meta-analysis aimed to determine the efficacy and safety of anti-IL-5 therapy in eosinophilic COPD.</p><p>Methods: We searched the PubMed, Web of Science, Embase, and Cochrane Library databases from inception to August 2020 (updated in June 2021) to identify studies comparing anti-IL-5 therapy (including mepolizumab, benralizumab, and reslizumab) with placebo in eosinophilic COPD patients.…”
  4. 11684

    DataSheet1_Preparation of rambutan-like Co0.5Ni0.5Fe2O4 as anode for high–performance lithium–ion batteries.PDF by Qian Wang (32718)

    Published 2022
    “…<p>NiFe<sub>2</sub>O<sub>4</sub> is a kind of promising lithium ion battery (LIB) electrode material, but its commercial applications have been limited due to the electronic insulation property and large volume expansion during the conversion reaction process, which results in rapid capacity decrease and poor cycling stability. We synthesized rambutan-like Co<sub>0.5</sub>Ni<sub>0.5</sub>Fe<sub>2</sub>O<sub>4</sub> using the self-templating solvothermal method. …”
  5. 11685
  6. 11686

    Subgroup analysis. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  7. 11687

    Study outcomes. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  8. 11688

    Number of structural scans per age group. by Stefania Conte (9349517)

    Published 2024
    “…Following the first steep increase in WM volume during infancy and childhood, the rate of development slows down in adulthood and decreases with aging. Similarly, microstructural properties of WM, particularly fractional anisotropy (FA) and mean diffusivity (MD), follow independent rates of change across the lifespan. …”
  9. 11689

    LP I<sub>h</sub> metamodulation is rapid and reversible. by Wulf-Dieter C. Krenz (693267)

    Published 2015
    “…The percent change in LP I<sub>h</sub> G<sub>max</sub> relative to t = 0 is plotted (mean±SEM, increases are positive, decreases are negative). …”
  10. 11690

    Knock-out of <i>atp6v1e1b</i> in zebrafish shows an early phenotypic read-out. by Lore Pottie (10994479)

    Published 2021
    “…Data are expressed as mean ± SD from 5 biological replicates. (C) Band intensities of fluorescence signals of atp6v1e1 and α-tubulin were quantified and normalized to the corresponding WT controls. …”
  11. 11691
  12. 11692
  13. 11693

    Supplemental figures for manuscript entitled: Tumor Suppressors RBL1 and PTEN are Epigenetically Silenced in IPF Mesenchymal Progenitor Cells by a CD44/Brg1/PRMT5 Regulatory Comple... by Craig Henke (9406202)

    Published 2024
    “…We demonstrate that expression of the tumor suppressor genes <i>rbl1</i> and <i>pten</i> is decreased in IPF MPCs. …”
  14. 11694

    Structural Studies of the <i>Methylosinus trichosporium</i> OB3b Soluble Methane Monooxygenase Hydroxylase and Regulatory Component Complex Reveal a Transient Substrate Tunnel by Jason C. Jones (9191264)

    Published 2020
    “…The kinetics of reaction of O<sub>2</sub> with the diferrous sMMOH:MMOB complex in solution show that use of the MMOB V41R variant decreases the rate constant for O<sub>2</sub> binding >25000-fold without altering the component affinity. …”
  15. 11695

    Structural Studies of the <i>Methylosinus trichosporium</i> OB3b Soluble Methane Monooxygenase Hydroxylase and Regulatory Component Complex Reveal a Transient Substrate Tunnel by Jason C. Jones (9191264)

    Published 2020
    “…The kinetics of reaction of O<sub>2</sub> with the diferrous sMMOH:MMOB complex in solution show that use of the MMOB V41R variant decreases the rate constant for O<sub>2</sub> binding >25000-fold without altering the component affinity. …”
  16. 11696

    Augmented Dicky-Fuller tests for unit roots. by Taimoor Ahmad (8940146)

    Published 2023
    “…A one percent increase in vaccinations decreased deaths by 0.38% (95% CI: -0.67, -0.08) in wave 5 and the association is statistically significant.…”
  17. 11697
  18. 11698
  19. 11699

    Adverse events <sup>a</sup>. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  20. 11700

    Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”